Background: Laparoscopic surgery is regarded as the gold standard for management of adnexal tumours due to many advantages. Currently, the exact size of the adnexal tumour contraindicating laparoscopic management has not been clearly defined. Some studies suggest laparotomy for the treatment of adnexal tumours larger than 8 to 10 cm. Risk of malignancy increases with large cysts. Issues with operation of huge adnexal masses are limited surgical field, difficulty in inserting trocars and removing the specimen without rupture. This study aims to evaluate the feasibility and surgical outcomes of laparoscopic surgery for large adnexal masses.Methods: A prospective observational study was conducted in the Department of Obstetrics and Gynaecology, JSS Medical College, Mysuru.Results: 35 patients with large adnexal masses, which were thought to be benign, were subjected to laparoscopic surgery. Mean diameter of masses as per the pre-operative ultrasound measurements was 12.2cm (range: 10.1-20.4cm). The mean operative time was 51.15minutes, estimated blood loss was 85.4ml, duration of postoperative hospital stay was 2.8 days. Serous cystadenoma was the most common histopathological finding. However, one case of borderline tumour was found.Conclusions: The potential risk of malignancy is the most important limiting factor for laparoscopic management of large ovarian cysts. Therefore, it is necessary to establish risk profiles of patients with adnexal masses in order to benefit from minimally invasive surgery wherever possible. The current study supports laparoscopic management of large ovarian cysts as a technically feasible method if proper case selection is made.
COVID-19 infection during pregnancy may result in rapid deterioration of health of pregnant women and might affect the foetus also. Aim: To assess the awareness and factors inuencing the acceptance of covid19 vaccine among pregnant women Methodology: This study was conducted in the department of Obstetrics and Gynaecology, KIMS, Bangalore over three months. The antenatal patients visiting the outpatient department were included in the study. Those who have received two doses of vaccination already were excluded. A well-constructed questionnaire about the various factors associated with the vaccine was provided to all participants. Results: 580 pregnant women participated in the study and completed the questionnaire.31.4 % belonged to high risk pregnancy group. 85 % believed that vaccines in India have adequate efcacy and 72.9% were aware that vaccines have been approved during pregnancy.84.7% were worried that the vaccine is harmful to the foetus. 45.9% said that they would agree to take the vaccine willingly. However, 72.2 % stated that they will be willing to take the vaccine if counselled for it by their doctor. 44.9% of participants were willing to take the vaccine if counselled by the doctor, at the initial month of the study, which increased to 84.9% of the participants enrolled during the third month of the study. Conclusions: Vaccination is the most promising means of controlling the spread of the corona virus pandemic. Effective counselling of antenatal mothers by health care providers plays a pivotal role in promoting vaccine acceptance. Over time with increasing awareness, the acceptance of the vaccine among pregnant women is likely to show a steeply rising trend.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.